Holen Sie sich die Stockscreener-App
18.23
4.17%
0.73
Handel nachbörslich:
18.23
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Warmuth, Monte Rosa Therapeutics CEO, sells $141k in Glue stock - Investing.com Australia
[Form 4] Monte Rosa Therapeutics, Inc. Insider Trading Activity - Stock Titan
Markus Warmuth sells 5,466 shares of GLUE (NASDAQ: GLUE) under Rule 144 - Stock Titan
Edmund Dunn files Form 144 reporting GLUE (NASDAQ: GLUE) common stock sales - Stock Titan
Insider Sell: Philip Nickson Sells Shares of Monte Rosa Therapeutics Inc (GLUE) - GuruFocus
Monte Rosa Therapeutics Insider Sells Over $100K in Shares - National Today
Philip Nickson Sells 5,845 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock - MarketBeat
Insider at Monte Rosa Therapeutics (GLUE) sells 5,845 shares - Stock Titan
[144] Monte Rosa Therapeutics, Inc. SEC Filing - Stock Titan
26,117 GLUE shares reported for sale (NASDAQ: GLUE) in Form 144 - Stock Titan
GLUE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Performance Recap: Is Monte Rosa Therapeutics Inc forming a bullish divergenceCEO Change & Detailed Earnings Play Strategies - baoquankhu1.vn
Aug Momentum: Is Monte Rosa Therapeutics Inc subject to activist investor interest2026 Recap & Safe Entry Point Alerts - baoquankhu1.vn
GLUE Technical Analysis | Trend, Signals & Chart Patterns | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
Monte Rosa Therapeutics (GLUE) grants equity awards to accounting chief - Stock Titan
Monte Rosa Therapeutics (NASDAQ: GLUE) officer reports stock and option holdings in Form 3 - Stock Titan
Investor Mood: How sensitive is Monte Rosa Therapeutics Inc to inflationTrend Reversal & Proven Capital Preservation Tips - baoquankhu1.vn
Analysts’ Top Healthcare Picks: Nurix Therapeutics (NRIX), Immunocore Holdings (IMCR) - The Globe and Mail
Quarterly Earnings: How sensitive is Monte Rosa Therapeutics Inc to inflation2026 Sector Moves & Community Verified Watchlist Alerts - baoquankhu1.vn
Gainers Report: What are the risks of holding Monte Rosa Therapeutics IncRisk Management & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Aug Patterns: Can Monte Rosa Therapeutics Inc lead its sector in growth2026 Technicals & Weekly Momentum Picks - baoquankhu1.vn
Does J&J-Backed MRT-2359 Prostate Cancer Trial Change The Bull Case For Monte Rosa Therapeutics (GLUE)? - simplywall.st
Trading Recap: Will Monte Rosa Therapeutics Inc benefit from AI trends2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Johnson & Johnson MRT-2359 Trial Supply Agreement - Sahm
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Monte Rosa Therapeutics urges new pathways for the next generation of scientists - Traders Union
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
Aug Ideas: Can Monte Rosa Therapeutics Inc lead its sector in growthQuarterly Trade Review & Smart Investment Allocation Tips - baoquankhu1.vn
Can Monte Rosa Therapeutics Inc lead its sector in growthTrade Ideas & Long-Term Capital Growth Ideas - baoquankhu1.vn
Breakouts Watch: How sensitive is Monte Rosa Therapeutics Inc to inflationQuarterly Market Review & Growth Focused Stock Reports - baoquankhu1.vn
Big Picture: Does Monte Rosa Therapeutics Inc stock have upside surprise potentialRate Hike & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story - Yahoo Finance
Wall Street Zen Downgrades Monte Rosa Therapeutics to 'Sell' - National Today
Monte Rosa Therapeutics (NASDAQ:GLUE) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Risks Report: Is Monte Rosa Therapeutics Inc forming a bullish divergenceQuarterly Earnings Summary & Verified Technical Signals - baoquankhu1.vn
Does Monte Rosa Therapeutics Inc stock have upside surprise potential - baoquankhu1.vn
NEA group (NASDAQ: GLUE) discloses 9.6% Monte Rosa ownership - Stock Titan
Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Lantheus (LNTH) and Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results, Misses Estimates By $0.10 EPS - MarketBeat
Guggenheim Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $30.00 - MarketBeat
Monte Rosa Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Monte Rosa Therapeutics price target lowered to $30 from $34 at Guggenheim - TipRanks
Monte Rosa Therapeutics (GLUE) Quarterly Loss Tests Bullish Profitability Narrative - simplywall.st
Monte Rosa (GLUE) Reports Wider Q4 Loss of $0.55/Share vs $0.34 Estimate, Revenue Misses - AlphaStreet
Analysts Are Bullish on Top Healthcare Stocks: Alto Neuroscience, Inc. (ANRO), Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Monte Rosa Therapeutics Reports Positive Clinical Data and $345M Financing, Advancing Multiple Phase 2 Trials into 2029 - Minichart
Is Monte Rosa Therapeutics Inc stock a hidden gem2026 Earnings Surprises & Advanced Technical Signal Analysis - baoquankhu1.vn
Monte Rosa Therapeutics (GLUE) reports Q4 loss, misses revenue estimates - MSN
Monte Rosa Therapeutics, Inc. (GLUE) Reports Wider Loss Q4 EPS Estimates by 63.4% - AlphaStreet
Monte Rosa’s QuEEN™ Discovery Engine: AI-Driven Molecular Glue Degraders Targeting Undruggable Proteins in Biotechnology 4145465158 - Minichart
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Monte Rosa Therapeutics: Fourth Quarter Financial Results Overview - Bitget
Monte Rosa Therapeutics, Inc. Announces Executive Changes - marketscreener.com
Monte Rosa Therapeutics (GLUE) 2025 Financials: Q4 Loss, Revenue MissNews and Statistics - IndexBox
Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans - MarketBeat
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Investing News Network
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Monte Rosa Therapeutics Swings to Net Loss in Q4, Collaboration Revenue Falls - marketscreener.com
Monte Rosa Therapeutics: Q4 Earnings Snapshot - Barchart
Monte Rosa Therapeutics : Corporate Presentation – March 2026 - marketscreener.com
Monte Rosa Therapeutics (NASDAQ: GLUE) touts MGD pipeline and major Novartis, Roche deals - Stock Titan
Monte Rosa Therapeutics Q4 revenue drops, net loss widens on lower milestone payments - TradingView
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q4 Revenue $2.8M - marketscreener.com
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):